10.97

5.89% 0.61

After Hours: 10.97

Neuropace Inc (NPCE)

Overview News Price History Financials Discussions Forecast

Neuropace Inc stock is traded at $10.97, with a volume of 194.12K. It is up +5.89% in the last 24 hours and down -9.26% over the past month. NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Previous Close:

$10.36

Open:

$10.35

24h Volume:

194.12K

Relative Volume:

1.02

Market Cap:

$357.18M

Revenue:

$65.42M

Net Income/Loss:

$-32.96M

P/E Ratio:

-8.6378

EPS:

-1.27

Net Cash Flow:

$-19.87M

1W Performance:

-5.67%

1M Performance:

-9.26%

6M Performance:

+51.73%

1Y Performance:

-19.75%

1-Day Range:

$10.24

$11.09

1-Week Range:

$9.56

$11.63

52-Week Range:

$5.45

$15.77

Neuropace Inc Stock (NPCE) Company Profile

Name

Neuropace Inc

Sector

Healthcare (1172)

Industry

Medical Devices (161)

Phone

(650) 237-2700

Address

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Employee

184

Twitter

Next Earnings Date

2025-03-04

Latest SEC Filings

NPCE's Discussions on Twitter

Compare NPCE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NPCE Neuropace Inc	10.97	357.18M	65.42M	-32.96M	-19.87M	-1.27
ABT Abbott Laboratories	130.28	225.95B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	96.42	142.29B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	363.84	138.83B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	91.51	117.34B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	68.51	40.28B	5.72B	4.17B	259.90M	6.97

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-21-25	Initiated	UBS	Buy
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-30-24	Initiated	Leerink Partners	Outperform
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-22-23	Initiated	Lake Street	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform
May-17-21	Initiated	JP Morgan	Overweight
May-17-21	Initiated	Morgan Stanley	Overweight
May-17-21	Initiated	SVB Leerink	Outperform
May-17-21	Initiated	Wells Fargo	Overweight

View All

Neuropace Inc Stock (NPCE) Latest News

Mar 12, 2025

NeuroPace’s SWOT analysis: stock poised for growth amid expanding market - Investing.com

Mar 12, 2025

Analysts Set Expectations for NeuroPace FY2025 Earnings - MarketBeat

Mar 12, 2025

Mar 10, 2025

NeuroPACE at Leerink’s Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada

Mar 10, 2025

Cantor Fitzgerald maintains NeuroPace stock target at $20 By Investing.com - Investing.com Canada

Mar 10, 2025

Cantor Fitzgerald maintains NeuroPace stock target at $20 - Investing.com

Mar 10, 2025

Mar 09, 2025

NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results - MarketBeat

Mar 09, 2025

Cantor Fitzgerald Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat

Mar 09, 2025

Mar 08, 2025

Cantor Fitzgerald Expects Increased Earnings for NeuroPace - Defense World

Mar 08, 2025

Mar 07, 2025

NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St

Mar 07, 2025

NeuroPace (NASDAQ:NPCE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - Defense World

Mar 07, 2025

Mar 06, 2025

NeuroPace Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Mar 06, 2025

NeuroPace: Strong Financial Performance and Strategic Initiatives Drive Buy Rating - TipRanks

Mar 06, 2025

Mar 05, 2025

NeuroPace, Inc. Reports Strong 2024 Growth Despite Challenges - TipRanks

Mar 05, 2025

Cantor raises NeuroPace stock price target to $20, maintains overweight - Investing.com India

Mar 05, 2025

What 4 Analyst Ratings Have To Say About NeuroPace - Benzinga

Mar 05, 2025

NeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 05, 2025

Cantor raises NeuroPace stock price target to $20, maintains overweight By Investing.com - Investing.com South Africa

Mar 05, 2025

NeuroPace Q4 2024 revenue increases 19% to USD 21.5M - Medical Buyer

Mar 05, 2025

NeuroPace Inc.: Q4 Earnings Snapshot - Midland Daily News

Mar 05, 2025